We provide you with 20 years of free, institutional-grade data for KRYS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of KRYS. Explore the full financial landscape of KRYS stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-04 | 1711279 | KRYS | 10-Q | Url |
| 2025-05-06 | 1711279 | KRYS | 10-Q | Url |
| 2025-02-19 | 1711279 | KRYS | 10-K | Url |
| 2024-11-04 | 1711279 | KRYS | 10-Q | Url |
| 2024-08-05 | 1711279 | KRYS | 10-Q | Url |
| 2024-05-06 | 1711279 | KRYS | 10-Q | Url |
| 2024-02-26 | 1711279 | KRYS | 10-K | Url |
| 2023-11-06 | 1711279 | KRYS | 10-Q | Url |
| 2023-08-07 | 1711279 | KRYS | 10-Q | Url |
| 2023-05-08 | 1711279 | KRYS | 10-Q | Url |
| 2023-02-27 | 1711279 | KRYS | 10-K | Url |
| 2022-11-07 | 1711279 | KRYS | 10-Q | Url |
| 2022-08-08 | 1711279 | KRYS | 10-Q | Url |
| 2022-05-09 | 1711279 | KRYS | 10-Q | Url |
| 2022-02-28 | 1711279 | KRYS | 10-K | Url |
| 2021-11-08 | 1711279 | KRYS | 10-Q | Url |
| 2021-08-09 | 1711279 | KRYS | 10-Q | Url |
| 2021-05-10 | 1711279 | KRYS | 10-Q | Url |
| 2021-03-01 | 1711279 | KRYS | 10-K | Url |
| 2020-11-09 | 1711279 | KRYS | 10-Q | Url |
| 2020-08-07 | 1711279 | KRYS | 10-Q | Url |
| 2020-05-04 | 1711279 | KRYS | 10-Q | Url |
| 2020-03-10 | 1711279 | KRYS | 10-K | Url |
| 2019-11-04 | 1711279 | KRYS | 10-Q | Url |
| 2019-08-05 | 1711279 | KRYS | 10-Q | Url |
| 2019-05-07 | 1711279 | KRYS | 10-Q | Url |
| 2019-03-12 | 1711279 | KRYS | 10-K | Url |
| 2018-11-05 | 1711279 | KRYS | 10-Q | Url |
| 2018-08-06 | 1711279 | KRYS | 10-Q | Url |
| 2018-05-07 | 1711279 | KRYS | 10-Q | Url |
| 2018-03-12 | 1711279 | KRYS | 10-K | Url |
| 2017-11-13 | 1711279 | KRYS | 10-Q | Url |
| 2017-08-21 | 1711279 | KRYS | S-1 | Url |
Krystal Biotech, Inc(NASDAQ:KRYS) 
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullo...
Website: http://www.krystalbio.com
Founded: 2015
Full Time Employees: 51
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about KRYS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.